trending Market Intelligence /marketintelligence/en/news-insights/trending/IZFb4xWPjMkofQ4w19Z4iw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Roche hemophilia drug sees positive phase 3 study results

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Roche hemophilia drug sees positive phase 3 study results

Roche Holding Ltd.'s hemophilia A drug candidate met its primary- and- secondary endpoints in a phase 3 study.

ACE910, or emicizumab, showed a significant reduction in the number of bleeds over time in 12-year-old patients and older when compared to no prophylactic treatment.

The company also said it had resolved the thrombosis concerns raised earlier during the trial.